← board
NSRX
Nasus Pharmadistress 8/10 · high distress / dilution risk$2.900%today-68% from 52w high
Lead: Anaphylaxis Food
Revenue
$1235M
Liquidity
$1M
Runway
0.3 yrs
Shares 1y
—
Price & events
-56.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-5.5%
1W
-12.1%
1M
-14.7%
3M
-53.6%
6M
—
1Y
—
2Y
—
5Y
-64.8%
All
Overview
- Market Cap
- $26.14M
- Volume
- 302
- 52 Week Range
- $2.01 – $9.15
- Total Shares
- 9.02M
- Float Shares
- 4.86M
- Short %
- 2.63%
- % Held by Insiders
- 49.17%
- % Held by Institutions
- 18.57%
- RVOL
- 0.01x
Pipeline stages · 1 programs
FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC, Epinephrine autoinjector double dose, FMXIN002 double dose
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-12 | Phase 2/3 | — | Anaphylaxis Food | 30 | enrolling by invitation |
| 2026-03 | Phase 1/2 | FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC, Epinephrine autoinjector double dose, FMXIN002 double dose | Anaphylaxis, Allergy | 50 | enrolling by invitation |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $20 (+578% upside) · 3 analysts
- 2026-03-26CitizensMarket Outperform
- 2025-12-18CitizensMarket Outperform
- 2025-09-29Laidlaw & Co.Buy
Competitors — Anaphylaxis Food
- none identified
Recent news
- 2026-07-23Nasus Pharma (NSRX) Stock Forecast and Price Target 2026 - MarketBeat
- 2026-07-13Enterprise value to EBIT forward of Nasus Pharma Ltd. – AMEX:NSRX - TradingView
- 2026-07-12Nasus Pharma Shares Dip as Stock Consolidates Near Support Levels - Trend Following Picks - dars.gov.et
- 2026-07-04Price to sales forward of Nasus Pharma Ltd. – AMEX:NSRX - TradingView
- 2026-06-26NSRX Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-22Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum - The Manila Times
- 2026-06-22Nasus Pharma lines up live June 24 investor forum appearance - Stock Titan
- 2026-06-09Nasus Pharma Announces Positive Results from Preclinical - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.